Wendy Lane

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 286 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +9

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study

John B. Buse, Satish K. Garg, Julio Rosenstock et al. · Diabetes Care · 2018 · 218 citations · Full text

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes

Wendy Lane, Timothy S. Bailey, Gregg Gerety et al. · JAMA · 2017 · 205 citations

Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII

Irl B. Hirsch, Bruce W. Bode, Satish K. Garg et al. · Diabetes Care · 2005 · 199 citations

Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force

George Grunberger, Jill M. Abelseth, Timothy S. Bailey et al. · Endocrine Practice · 2014 · 178 citations

Metabolic Syndrome, Diabetes Management, Health Policy +10